English 
Pediatric Crohn’s Disease (pCD)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00
Despite the availability of current therapeutics, there remains the unmet need for more effective treatment to reduce the recurrence rate which is quite high. Emerging drugs like Mirikizumab (Eli Lilly and Company), Stelara (Janssen Research & Development, LLC), Entyvio(Takeda Oncology), and others are likely capable to eliminate the current challenges and also have the potential to drive the market size of pediatric Crohn’s Disease (pCD). The reduced cost of biosimilars relative to Pediatric Crohn’s disease can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments.
Description
Pediatric Crohn’s Disease (pCD) is a rare condition commonly referred to as inflammatory bowel disease (IBD) which are immunologically mediated inflammatory disease of the gastrointestinal tract occurring in children and adolescence. It typically affects the terminal ileum but can discontinuously affect the entire gastrointestinal tract and commonly leads to complications such as fistulas, abscesses, and stenosis. Although, there is no cure for Crohn’s disease, with proper treatment and support the disease can be effectively managed and may go into remission for long periods of time.
In the long-term, pediatric Crohn’s disease remains an attractive indication for drug development, with a rich clinical pipeline. Amid an increasingly competitive commercial landscape), we continue to view pediatric Crohn’s disease as an attractive indication for drug development; no therapy in development has demonstrated ‘game-changing’ or meaningfully differentiated efficacy, leaving room for new entrants to compete. Among earlier-stage mechanisms, physicians indicate enthusiasm for additional safe, effective oral agents and may theoretically drive greater efficacy in select patient populations.
Pediatric Crohn’s Disease (pCD) – Prevalence (Epidemiology)
The diagnosis of Pediatric Crohn’s Disease requires the integration of clinical presentation, laboratory tests, and endoscopic, histologic, pathologic, and radiologic findings. In 2017, an expert panel, which included contributors from the Society of Abdominal Radiology Crohn’s Disease–Focused Panel, the Society of Pediatric Radiology, and the American Gastroenterological Association, issued the guidelines on the use of computed tomography enterography (CTE) and magnetic resonance enterography (MRE) in patients with small bowel Crohn disease.
Pediatric Crohn’s disease (pCD) is a rare, inflammatory bowel disease characterized by severe, chronic inflammation of the intestinal wall or any portion of the gastrointestinal tract. Crohn’s Disease is most common in individuals between 15-35, with approximately 25% diagnosed by age 20. The total prevalent cases in the G7 countries are anticipated to rise from XX in 2018 to ~85,000 by 2032 at a CAGR of XX for the study period (2018–2032)”
Pediatric Crohn’s Disease (pCD)– Current Market Size & Forecast Trends
The most widely used drugs in Crohn’s Disease are corticosteroids, immunosuppressants, and biologicals (anti-TNF, anti-interleukins, and anti-integrins). The landscape of pediatric Crohn’s disease (CD) is rapidly changing. Therapeutic advances seen in the adult arena are rapidly adopted by pediatric gastroenterologists and evaluated in both controlled studies and real-world experience. Additionally, pediatrics is leading the way in primary therapy that uses regimens including diet-specific carbohydrates (SCD) and exclusive enteral nutrition (EEN). With the advent of the market entry of anticancer necrosis factor alpha (TNF-α) inhibitors, the market landscape has changed with more effective drugs with the potential for prolonged remission.
The pediatric Crohn’s disease market is poised for continued growth as next-generation agents reach the market. The pediatric Crohn’s disease market approached ~$170 million in sales in 2018 in G7 countries and is expected to reach ~$1 Billion by 2032. Despite market growth, response rates to existing therapies remain suboptimal, and patients often lose response over time; as a result, patients commonly cycle through multiple chronic therapies. The propensity for patients to cycle through therapies enables new entrants to garner share and supports several therapeutic classes; among near-term entrants, we expect oral S1P receptor modulators, and IL-23 mAbs may all achieve blockbuster class sales. The primary drivers of this growth will be the uptake of emerging drugs i.e., Mirikizumab (Eli Lilly), SGX203 (Soligenix ), STAT-201 (Statera Biopharma) and others.
Report Highlights
- Pediatric Crohn’s Disease (pCD)– Current Market Trends
- Pediatric Crohn’s Disease (pCD)– Current & Forecasted Cases across the G7 Countries
- Pediatric Crohn’s Disease (pCD)– Market Opportunities and Sales Potential for Agents
- Pediatric Crohn’s Disease (pCD)– Patient-based Market Forecast to 2032
- Pediatric Crohn’s Disease (pCD)– Untapped Business Opportunities
- Pediatric Crohn’s Disease (pCD)– Product Positioning Vis-a-vis Competitors’ Products
- Pediatric Crohn’s Disease (pCD)– KOLs Insight
Additional information
| Price | 2-3 User License, Enterprise License, Single User License, Site License |
|---|
Table of Contents
-
- Executive Summary
- Key Findings
- Pediatric Crohn’s Disease: Current and Emerging Trends
- Pediatric Crohn’s Disease Background
- Pediatric Crohn’s disease Definition
- Signs and Symptoms
- Causes
- Pathophysiology
- Diagnosis
- Epidemiology Estimated and Forecast to 2032
- Key Findings
- Methods and data Sources
- Country Specific Prevalent Cases of Pediatric Crohn’s Disease (US, Germany, France, Italy, Spain, UK, and Japan)
- Country Specific Treated Cases of Pediatric Crohn’s disease by Therapies
- Key Sources for Pediatric Crohn’s disease Epidemiology and Model Parameters
- United States
- United States Prevalent cases of Pediatric Crohn’s disease
- United States Treated Cases of Pediatric Crohn’s disease by Therapies
- Germany
- Germany Prevalent cases of Pediatric Crohn’s disease
- Germany Treated Cases of Pediatric Crohn’s disease by Therapies
- France
- France Prevalent cases of Pediatric Crohn’s disease
- France Treated Cases of Pediatric Crohn’s disease by Therapies
- Italy
- Italy Prevalent cases of Pediatric Crohn’s disease
- Italy Treated Cases of Pediatric Crohn’s disease by Therapies
- Spain
- Spain Prevalent cases of Pediatric Crohn’s disease
- Spain Treated Cases of Pediatric Crohn’s disease by Therapies
- United Kingdom
- United Kingdom Prevalent cases of Pediatric Crohn’s disease
- United Kingdom Treated Cases of Pediatric Crohn’s disease by Therapies
- Japan
- Japan Prevalent cases of Pediatric Crohn’s disease
- Japan Treated Cases of Pediatric Crohn’s disease by Therapies
- United States
- Current Therapies and Medical Practice
- Key Findings
- Treatment Guidelines
- Marketed Therapies Chapters
- Adalimumab (AbbVie/MedImmune)
- Infliximab (Janssen Biotech)
- Pentasa (Kyorin Pharmaceutical/Ferring Pharmaceuticals)-
- Unmet Needs
- Emerging Therapies
- Pipeline Overview
- Therapeutic Developments Pipeline for Pediatric Crohn’s Disease
- Product Analysis
- Mirikizumab (Eli Lilly and Company)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Ustekinumab (Janssen Research & Development, LLC)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Vedolizumab (Takeda Oncology)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Ozanimod (Bristol Myers Squibb)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Mirikizumab (Eli Lilly and Company)
- Product Analysis
- Emerging Therapies
-
- Product Analysis
- STAT-201 (Statera Biopharma, Inc. [Formerly Cytocom, Inc.)]
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Etrolizumab (Genentech/Hoffmann-La Roche)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- SGX203 (Soligenix Inc.)
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- CERC-002 (Avalo Therapeutics, Inc. (Formerly Cerecor Inc.))
- Product Profile
- Clinical Development
- Sales & Market Opportunity by 2032
- Alofisel (Takeda)
- Product Profile
- Clinical Development
- Thetanix (4d pharma)
- Product Profile
- Clinical Development
- RBX-2660 (Rebiotix/Ferring)
- Product Profile
- Clinical Development
- STAT-201 (Statera Biopharma, Inc. [Formerly Cytocom, Inc.)]
- Product Analysis
-
- Pediatric Crohn’s Disease- Cost Burden & Prescriptions survey
- Future Treatment Paradigm
- Pediatric Crohn’s Disease Competitor Landscape and Approvals Anticipated
- Future Treatment Algorithms and Competitor Positioning
- Key Data Summary for Emerging Treatment
- Annual Cost of Current & Emerging Therapies
- Market Outlook
- Key Findings
- Country Specific Market Forecast to 2032
- G7 total Market for Pediatric Crohn’s Disease 2022-2032 (USD Million)
- G7 total Market for Pediatric Crohn’s Disease by Therapies 2022-2032 (USD Million)
- Market Forecast by Country
- United States
- United States Market for Pediatric Crohn’s Disease 2022-2032 (USD Million)
- United States Market for Pediatric Crohn’s Disease by Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for Pediatric Crohn’s Disease 2022-2032 (USD Million)
- Germany Market for Pediatric Crohn’s Disease by Therapies 2022-2032 (USD Million)
- France
- France Market for Pediatric Crohn’s Disease 2022-2032 (USD Million)
- France Market for Pediatric Crohn’s Disease by Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for Pediatric Crohn’s Disease 2022-2032 (USD Million)
- Italy Market for Pediatric Crohn’s Disease by Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for Pediatric Crohn’s Disease 2022-2032 (USD Million)
- Spain Market for Pediatric Crohn’s Disease by Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for Pediatric Crohn’s Disease 2022-2032 (USD Million)
- United Kingdom Market for Pediatric Crohn’s Disease by Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for Pediatric Crohn’s Disease 2022-2032 (USD Million)
- Japan Market for Pediatric Crohn’s Disease by Therapies 2022-2032 (USD Million)
- United States
- Market Drivers and Constraints
- What Factors Are Driving the Market for Pediatric Crohn’s Disease?
- What Factors Are Constraining the Market for Pediatric Crohn’s Disease?
- Executive Summary
Appendix
Sample Enquiry
Related products
-
Prader-Willi Syndrome (PWS)| Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2032
$6,989.00 – $20,967.00Select optionsThe Prader-Willi Syndrome (PWS) market is hugely contributed by current standard of care (human growth hormone therapy) as there is no cure for PWS. By 2032, the market is expected to change due to the uptake and launch of new novel therapies. In a PWS treatment setting, the current SoC will decline, and the novel emerging drugs will grasp the highest market shares. The sales of the emerging therapies for the treatment of PWS in the study countries (United States, France, Germany, Italy, Spain, United Kingdom and Japan) will experience high growth over the 2018-2032 study period, adding a value estimated at a total market of $ 2.1 billion by 2032.
-
Peripheral T-cell lymphoma (PTCL)| Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsMellalta’s analysts estimate that the United States market is expected to show rapid growth, mainly attributed to, the launch of Adcetris in the front-line setting and expected approval of the potential therapies in the pipeline during the forecast period (2021-2030). Through this, the market size is set to show an extensive jump and grow at a CAGR of 15.3%
-
Acute Myeloid Leukemia (AML) –Tumour Slide Deck 2023
$11,800.00 – $20,000.00
$5,900.00 – $10,000.00Select optionsThe research study conducted by Mellalta Meets provides insights into the AML market dynamics, treatment trends, and key opportunities in the G7 regions. It highlights the need for novel targeted therapies, the potential of biomarker strategies, and the significant market opportunity for drug developers targeting the AML population. The study serves as a comprehensive resource for understanding the current landscape and future prospects of AML treatment.